6 个月无进展生存期（PFS6）作为接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者的预后因素：一项真实世界多中心研究

Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved overall survival (OS) in relapsed or refractory large B-cell lymphomas (R/R LBCL).

However, factors associated with outcomes of CAR-T cell therapy in patients with R/R LBCL have not been fully elucidated. And limited evidence supports the use of early endpoints to evaluate the efficacy and long-term survival. Progression-free survival (PFS) at 6 months (PFS6) was defined as being alive and free of relapse or progression within 6 months of CAR-T cell infusion.

We aimed to assessed OS stratified by PFS6 by analyzing data from 71 R/R LBCL patients treated with CAR-T therapy across 2 hospitals. Subsequent OS was defined from the time of PFS6 or progression within 6 months to death. Among them, 58% reached PFS6. Compared with patients failed to achieve PFS6, 1-year OS was 91. 3% vs. 40. 2% and 2-year OS was 91. 3% vs. 32. 1%, respectively.

Patients achieving PFS6 had excellent outcome, whereas patients exhibiting earlier progression had a poor survival. Key predictors of PFS failure included older age (> 60) (P = 0. 040, OR:3. 40, 95%CI:1. 06 10. 93), lower pretransfusion hemoglobin level (P = 0. 019 OR:0. 27, 95%CI:0. 09 0. 81), and higher IFN- level (P = 0. 022, OR:2. 00, 95% CI:1. 66 4. 08). This insight could aid in risk stratification and support the use of PFS6 as a surrogate endpoint in clinical trials.